Distinctive patterns of Her-2/Neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers

Communications in Clinical Cytometry

Volumn 46, Issue 3, 2001, Pages 136-149

  Janocko, Laura E ^a   Brown, Kathryn A ^a   Smith, Charles A ^a   Gu, Ling Ping ^b   Pollice, Agnese A ^b   Singh, Sarita G ^b   Julian, Thomas ^b   Wolmark, Norman ^b   Sweeney, Lillian ^b   Silverman, Jan F ^b   Shackney, Stanley E ^b  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aneuploidy; Breast cancer; c myc; Cyclin D1; Her 2 neu; p53

Indexed keywords

CYCLIN D1;

ARTICLE; BREAST CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE C MYC; ONCOGENE NEU; PRIORITY JOURNAL;

ALLELES; ANEUPLOIDY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOMES, HUMAN, PAIR 17; CYCLIN D1; DISEASE PROGRESSION; GENES, P53; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; PHENOTYPE; PLOIDIES; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2;

EID: 0035875106     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.1098     Document Type: Article

References (69)

1. Genetic instabilities in human cancers
2. Microallel-typing defines the sequence and tempo of allelic losses at tumor suppressor gene loci during colorectal cancer progression
3. Genetic divergence in the clonal evolution of breast cancer
4. Frequent genetic heterogeneity in the clonal evolution of gynecologic carcinosarcoma and its influence on phenotypic diversity
5. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups
6. Common patterns of genetic evolution in human solid tumors
7. Genetic alterations in primary bladder cancers and their metastases
8. Separating favorable from unfavorable prognostic markers in breast cancer: The role of E-cadherin
9. Genetic instability in colorectal cancers
10. A genetic model for colorectal tumorigenesis
11. Immunohistochemical studies of early breast cancer evolution
12. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation
13. 17P (p53) allelic losses, 4N (G2/tetraploid) populations and progression to aneuploidy in Barrett's esophagus
14. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy
15. Evolution of neoplastic cell lineages in Barrett oesophagus
16. Stabilized p53 facilitates aneuploid clonal divergence in colorectal cancer
17. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma
18. Corrrelations among p53, Her-2/neu, and ras overexpresison and aneuploidy by multiparameter flow cytometry in human breast cancer: Evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas
19. Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins
20. Karyotypic evolution of a human undifferentiated large cell carcinoma of the lung in tissue culture
21. Model for the genetic evolution of human solid tumors
22. Discrepancies between flow cytometric and cytogenetic studies in the detection of aneuploidy in human solid tumors
23. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
24. The significance of oncogene amplification in primary breast cancer
25. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma
26. ERBB2 amplification in breast cancer analyzed by flourescence in situ hybridization
27. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
28. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
29. In vivo amplification and rearrangement of c-myc oncogene in human breast tumors
30. Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene
31. Cyclin D1 in breast cancer
32. Immunohistochemical profile of invasive lobular carcinoma of the breast: Predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive
33. The transforming and suppressor functions of p53 alleles: Effects of mutations that disrupt phosphorylation, oligomerization, and nuclear translocation
34. Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation
35. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumors cells
36. The p53 tumor suppressor gene in breast cancer
37. Mutations in the p53 gene occur in diverse human tumor types
38. The p53 tumour suppressor gene
39. p53 gene mutations inside and outside of exons 5-8: The patterns differ in breast and other tumors
40. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion
41. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas
42. Mdm2 promotes the rapid degradation of p53
43. Regulation of p53 stability by mdm2
44. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status
45. Significant differences in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas
46. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro
47. p53 protein expression in human breast carcinoma: Relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor
48. p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiological risk factors, histologic features, and prognosis
49. Spontaneous abnormalities in normal fibroblasts from patients with Li-Frauameni cancer syndrome: Aneuploidy and immortalization
50. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
51. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant P53 alleles
52. A p53-dependent mouse spindle checkpoint
53. 2 checkpoint is maintained by redundant pathways
54. Abnormal centrosome amplification in the absence of p53
55. Centrosome hyperamplification in human cancer: Chromosome instability induced by p53 mutation and/or Mdm2 overexpression
56. Genomic instability in MycER-activated Rat1A-MycER cells
57. MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification
58. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis, and chromosomal instability
59. c-myc overexpression and p53 loss cooperate to promote genomic instability
60. Cyclin D1 protein expression and function in human breast cancer
61. Cyclin D1 expression in invasive breast cancer
62. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast
63. Differential expression of cyclin D1 in breast papillary carcinomas and benign papillomas
64. Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer
65. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: Correlation with poor prognosis
66. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia
67. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
68. Genetic alterations of the c-myc protooncogene (MYC) in human primary breast carcinomas
69. Oncogene organisation and expression: Prediction in breast cancer